Chronic Kidney Disease Market Poised for Significant Growth Through 2034

The global chronic kidney disease (CKD) market is expected to expand steadily over the next decade as rising disease prevalence, earlier diagnosis, and continued pharmaceutical innovation drive demand for new treatment options.

Industry estimates indicate that the CKD therapeutics market across the seven major markets (the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan) was valued at approximately $4.8 billion in 2024. The market is projected to grow significantly through 2034 as more therapies reach patients and the treated population continues to expand.

Rising Prevalence Driving Market Expansion

Chronic kidney disease remains a major global health concern. Across the seven major pharmaceutical markets, there were an estimated 82 million prevalent CKD cases in 2024, with the United States accounting for the largest share.

Several long-term trends are contributing to the growing patient population:

• Increasing rates of diabetes and hypertension, the leading causes of kidney disease
• Aging populations across developed healthcare systems
• Expanded screening and early diagnostic capabilities
• Greater awareness among physicians and patients

These factors are expected to drive continued growth in demand for CKD therapies in the coming years.

Companies Advancing CKD Therapies

A number of pharmaceutical and biotechnology companies are actively developing treatments targeting chronic kidney disease and its related complications. Companies highlighted in the report include:

• AstraZeneca (NASDAQ: AZN)
• Boehringer Ingelheim (private)
• Mineralys Therapeutics (NASDAQ: MLYS)
• ProKidney (NASDAQ: PROK)
• Disc Medicine (NASDAQ: IRON)
• Regeneron Pharmaceuticals (NASDAQ: REGN)
• AION Healthspan (private)
• Amgen (NASDAQ: AMGN)
• Maze Therapeutics (NASDAQ: MAZE)

These companies are pursuing therapies designed to slow disease progression, address complications such as anemia and fluid imbalance, and improve overall kidney function outcomes.

Expanding Innovation in Nephrology

The treatment landscape for CKD continues to evolve as new drug classes and biologics enter clinical development. Researchers are focusing on therapies that can delay kidney failure, reduce complications, and potentially decrease the need for dialysis or transplantation.

With dozens of investigational therapies currently in development, the nephrology sector is attracting increased investment and scientific attention.

Investor Perspective

For investors, chronic kidney disease represents a growing opportunity within the broader cardiometabolic and renal therapeutics market. Companies that successfully develop therapies capable of slowing disease progression or improving long-term patient outcomes could benefit from a rapidly expanding global patient population.

Bottom Line

The chronic kidney disease market is positioned for meaningful growth through 2034, supported by rising disease prevalence and a robust pipeline of emerging therapies. As innovation continues to advance, pharmaceutical and biotechnology companies developing next-generation kidney disease treatments may play an increasingly important role in the evolving healthcare landscape.